
PARABILIS MEDICINES INC
PBLS · NASDAQ
更新於 2026-10-14 10:07:00
- 今日最高
- $29.50
- 今日最低
- $26.72
K線圖趨勢,實際資料以交易頁為準
關鍵數據
- 昨天開盤價
- $27.38
- 昨天收盤價
- $28.95
- 成交量
- 1.2M
- 市值
- $3.57B
- 市盈率(P/E)
- --
- 每股收益(EPS)
- $-2.04
昨天價格區間
52週價格區間
公司概況
- 板塊
- HEALTHCARE
- 行業
- Biotechnology
- 子行業
- BIOTECHNOLOGY
- 總部
- 30 ACORN PARK DRIVE, CAMBRIDGE, MA, UNITED STATES, 02140
- 國家
- US
- 上市日期
- 2026-06-10
- 財年截止
- December
- 流通股數
- 116.56M
- CIK
- --
- 官方網址
- parabilismed.com
Parabilis Medicines, Inc. (Ticker: PBLS) is an emerging company at the forefront of the telecommunications sector, dedicated to delivering innovative communication solutions tailored for both residential and commercial markets. The company leverages advanced technologies to enhance connectivity and customer experiences, positioning itself strategically for growth in the rapidly evolving digital landscape. With a strong focus on expanding its infrastructure and maintaining operational excellence, PBLS represents a compelling investment opportunity for institutional investors seeking to capitalize on the burgeoning demand for seamless communication services.
財務指標
營業收入
2026-06-30
$148K
2026-03-31
$0
2025-06-30
$0
2025-03-31
$0
營業支出
2026-06-30
$51.03M
2026-03-31
$47.45M
2025-06-30
$35.9M
2025-03-31
$40.24M
淨利潤
2026-06-30
-$52.46M
2026-03-31
-$45.31M
2025-06-30
-$34.81M
2025-03-31
-$38.32M
淨利潤率
2026-06-30
-35.44K%
2026-03-31
--
2025-06-30
--
2025-03-31
--
每股收益
2026-06-30
$-2.13
2026-03-31
--
2025-06-30
--
2025-03-31
--
息稅折舊攤銷前利潤
2026-06-30
-$51.66M
2026-03-31
-$44.41M
2025-06-30
-$35.9M
2025-03-31
-$37.27M
有效稅率
2026-06-30
--
2026-03-31
--
2025-06-30
--
2025-03-31
--
| 項目 | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| 營業收入 | $148K | $0 | $0 | $0 |
| 營業支出 | $51.03M | $47.45M | $35.9M | $40.24M |
| 淨利潤 | -$52.46M | -$45.31M | -$34.81M | -$38.32M |
| 淨利潤率 | -35.44K% | -- | -- | -- |
| 每股收益 | $-2.13 | -- | -- | -- |
| 息稅折舊攤銷前利潤 | -$51.66M | -$44.41M | -$35.9M | -$37.27M |
| 有效稅率 | -- | -- | -- | -- |
常見問題
風險提示
股價可能大幅波動,短時間內可能出現顯著漲跌。 數位資產與衍生性商品交易可能涉及槓桿、流動性等額外風險。 本頁內容僅供參考,不構成任何投資建議。 產品可用性與訪問可能因地區及適用法規而異。